News

Soleno Therapeutics Completes Target Enrollment in Ongoing DESTINY PWS Phase III Trial of DCCR in Prader Willi Syndrome

January 06, 2020

Company Continues to Expect Top-line Data in First Half of 2020 REDWOOD CITY, Calif. , Jan. 06, 2020 (GLOBE ...

Read More

Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2019 Financial Results

November 13, 2019

REDWOOD CITY, Calif. , Nov. 13, 2019 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage ...

Read More

Soleno Therapeutics Announces Closing of $15.4 Million Public Offering of Common Stock

October 25, 2019

REDWOOD CITY, Calif. , Oct. 25, 2019 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (SLNO), (“Soleno” or the “Company”), ...

Read More
Soleno – Home

Developing novel therapeutics for the treatment of rare diseases.

Pages

News and Events

Soleno Therapeutics Completes Target Enrollment in Ongoing DESTINY PWS Phase III Trial of DCCR in Prader Willi Syndrome

Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2019 Financial Results

Contact Us

  • 203 Redwood Shores Parkway
  • Suite 500
  • Redwood City, CA 94065